Literature DB >> 10334698

Talonavicular joint arthrodesis and Evans calcaneal osteotomy for treatment of posterior tibial tendon dysfunction.

C M Lombardi1, L N Dennis, F G Connolly, A D Silhanek.   

Abstract

The purpose of this study was to evaluate the combination of talonavicular fusion and Evans calcaneal osteotomy for the treatment of posterior tibial tendon dysfunction. This was a retrospective study of 10 patients, mean age 48.7 years, who had continued pain despite 6 months of conservative treatment and a minimum Johnson and Strom stage II deformity. Patients completed a detailed questionnaire, were physically examined, and their postoperative improvement was graded according to the American Orthopedic Foot and Ankle Society Ankle-Hindfoot Rating Scale. At a mean of 35 months (range 8-72 months) after surgery, patients demonstrated a significant improvement (p<.001) both in their subjective discomfort and in the structural alignment and function of their feet. The authors feel that this combination of procedures allows greater correction and stability than either procedure performed alone, and provides a viable alternative to triple arthrodesis.

Entities:  

Mesh:

Year:  1999        PMID: 10334698     DOI: 10.1016/s1067-2516(99)80022-2

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  3 in total

Review 1.  [Arthrodesis of the talonavicular joint].

Authors:  S Rammelt; R K Marti; H Zwipp
Journal:  Orthopade       Date:  2006-04       Impact factor: 1.087

2.  Exercise for posterior tibial tendon dysfunction: a systematic review of randomised clinical trials and clinical guidelines.

Authors:  Megan H Ross; Michelle D Smith; Rebecca Mellor; Bill Vicenzino
Journal:  BMJ Open Sport Exerc Med       Date:  2018-09-19

3.  The optimal procedure for lateral column lengthening calcaneal osteotomy according to anatomical patterns of the subtalar joint: an anatomical study in the Chinese population.

Authors:  Jiajun Wu; Hua Liu; Can Xu
Journal:  BMC Musculoskelet Disord       Date:  2022-08-05       Impact factor: 2.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.